Harvard Bioscience (HBIO) Total Liabilities (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Total Liabilities data on file, last reported at $67.9 million in Q1 2026.

• On a quarterly basis, Total Liabilities rose 4.5% year-over-year to $67.9 million in Q1 2026; TTM through Mar 2026 was $67.9 million, a 4.5% increase from a year earlier, with the FY2025 full-year figure at $66.3 million, up 4.79% from the prior year.
• Total Liabilities for Q1 2026 stood at $67.9 million, up from $66.3 million in the prior quarter.
• Over the last five years, Total Liabilities for HBIO reached as high as $81.7 million in Q1 2022 and fell as low as $61.7 million in Q2 2024.
• Historically, Total Liabilities has averaged $68.2 million across 5 years, with a median of $65.9 million in 2024.
• Across the five-year window, Total Liabilities advanced 10.16% in 2022 and declined 13.19% in 2023, its largest moves.
• Year by year, Total Liabilities stood at $73.1 million in 2022, then slipped by 12.1% to $64.3 million in 2023, then fell by 1.54% to $63.3 million in 2024, then grew by 4.79% to $66.3 million in 2025, then grew by 2.34% to $67.9 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $67.9 million in Q1 2026, $66.3 million in Q4 2025, and $63.9 million in Q3 2025.